Skip to content

ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy.

ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy of Benign or Malignant Tumors of the Uterus. A Stepped-wedge Cluster Randomized Clinical Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04063072
Acronym
ERAS-Gyneco
Enrollment
1800
Registered
2019-08-21
Start date
2019-09-01
Completion date
2021-10-31
Last updated
2021-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Neoplasms

Keywords

Hysterectomy, Uterine Cervical Neoplasms, Endometrial Neoplasms, Quality Improvement, Perioperative Care, Recovery of Function

Brief summary

The study assesses the impact on quality of care of implementing the ERAS (Enhanced Recovery After Surgery) protocol for hysterectomy of benign or malignant tumors of the uterus in the network of public hospitals in the Regione Piemonte (North-West Italy). Every hospital is a cluster entering the study treating patients according to its current clinical practice. On the basis of a randomized order, each hospital switches from current clinical practice to the adoption of the ERAS protocol.

Detailed description

ERAS (Enhanced Recovery After Surgery) protocol is a multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response following surgery. Even if efficacy and safety of ERAS protocol in gynaecological surgery is well-established in the literature, its implementation is limited to few selected centres in Piemonte. The aim of the study is to extend the implementation of the ERAS protocol to whole regional network of hospitals. Specific objectives are to estimate its impact on different dimensions of quality of care, including length of stay, complications and patient satisfaction, and to identify possible barriers or facilitating factors.

Interventions

PROCEDUREERAS protocol

In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.

Sponsors

Martini Hospital, Turin, Italy
CollaboratorOTHER
A.O.U. Città della Salute e della Scienza
CollaboratorOTHER
Ministry of Health, Italy
CollaboratorOTHER_GOV
Regione Piemonte
CollaboratorOTHER
Ospedale Regina Montis Regalis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

A stepped-wedge cluster randomized clinical trial. Each center starts as control group (usual care) and switch to experimental group (ERAS protocol implementation) according to a randomized order.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All the hospital wards within the Piemonte Region performing hysterectomy. * All the patients receiving an elective hysterectomy for benign or malignant tumors of the uterus.

Exclusion criteria

* Hospital wards performing less than 20 expected cases per year * Emergency hysterectomy * Hysterectomy for pelvic floor disorders * High severity cases not allowing ERAS protocol implementation (i.e. American Society of Anesthesiologists score: ASA V).

Design outcomes

Primary

MeasureTime frameDescription
Length of stay12 days after admissionMean length of stay calculated as difference between date of discharge and date of admission of the hospitalization for surgery, excluding length of stay \>12 days (98th percentile of the expected distribution).

Secondary

MeasureTime frameDescription
Length of stay >12 days30 days after admissionRate of patients with a length of stay \>12 days
Recovery after surgery24 hours after surgeryScore of quality of recovery at 24 hours after surgery, assessed with the questionnaire Quality of Recovery (QoR-15), a 15-items instrument, with responses recorded on a 11-point Likert-type scale form 0 (worst scenario) to 10 (best scenario) and an overall score ranging from 0 (poor recovery) to 150 (excellent recovery). A visual analogue scale (VAS), ranging from 0 (worst imaginable health state) to 10 (worst imaginable health state) is also supplied as summary evaluation.
Complications30 days after dischargeRate of surgical and medical complication after surgery For surgical complications: Comprehensive Complication Index
Transfer to intensive care unit30 days after surgeryRate of transfers to intensive care unit after surgery
Emergency visits after discharge30 days after dischargeRate of emergency visit in the first month after discharge
Hospital admissions after discharge30 days after dischargeRate of new admissions in the first month after discharge
Reintervention30 days after surgeryRate of reintervention in the first month after surgery, excluding planned interventions
Patients' satisfaction15 days after dischargeScore of patients' satisfaction measured 2 weeks after discharge, assessed with the questionnaire Surgical Satisfaction Questionnaire (SSQ8) supplied by telephone. SSQ8 is a 8-items instrument, with responses recorded on a 5-point Likert-type scale from 0 (worst scenario) to 4 (best scenario) and an overall score ranging from 0 (very unsatisfied) to 32 (very satisfied).
Healthcare costs30 days after dischargeMean healthcare costs from pre admission visit to 30 days after discharge

Countries

Italy

Contacts

Primary ContactAndrea Puppo, MD
andrea.puppo@aslcn1.it0039 0174677
Backup ContactMarco Camanni, MD
marco.camanni@aslcittaditorino.it0039 011 7095

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026